Pharmacotherapy plays a central role in obesity management, particularly with the emergence of incretin-based therapies such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic peptide (GIP)/GLP-1 receptor agonists. The gene discussed is GLP1R; the disease is obesity disorder.